LP-284 for Cancer
Trial Summary
What is the purpose of this trial?
This trial tests a new drug, LP-284, in adults with hard-to-treat cancers. It aims to find the safest dose and understand how the drug works in the body.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you must stop taking your current medications. However, you cannot have had any investigational or non-investigational anti-cancer therapy within 2 weeks or within at least 5 half-lives (up to a maximum of 4 weeks for biologics/immunotherapies) before starting the study drug.
Eligibility Criteria
This trial is for adults over 18 with relapsed or refractory lymphomas and solid tumors. Participants must be able to consent, have an ECOG performance status of 0-2, and meet specific criteria for measurable disease sites or assessable advanced lymphoma. They should also have certain liver and renal function levels.Inclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation (Phase 1a)
Participants receive escalating doses of LP-284 to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D)
Dose Expansion (Phase 1b)
Participants receive LP-284 at the RP2D to further evaluate safety and obtain preliminary estimates of clinical activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- LP-284 (Monoclonal Antibodies)
LP-284 is already approved in United States for the following indications:
- High-grade B-cell lymphoma with MYC and BCL2 rearrangements
- Mantle cell lymphoma